Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Equillium (Nasdaq: EQ) reported second quarter 2026 results and corporate updates focused on advancing lead asset EQ504, a selective aryl hydrocarbon receptor modulator. The company plans to submit its Phase 1 dossier in Australia imminently, with a proof‑of‑mechanism SAD/MAD study in healthy volunteers expected to start in Q4 2026 and topline data about six months later.
Equillium is also conducting IND‑enabling work to develop EQ504 as an inhaled therapy for inflammatory lung diseases and EQ302 for celiac disease, and has formed a Clinical Advisory Board for the ulcerative colitis program. Cash and cash equivalents were $57.2 million on June 30, 2026, up from $30.3 million at year‑end 2025, which Equillium believes can fund current plans into 2029. Q2 2026 R&D expenses were $2.8 million and G&A $2.4 million, leading to a net loss of $4.7 million, or $(0.04) per share, compared with a $5.7 million loss a year earlier.
Positive
- Cash and cash equivalents $57.2M at June 30, 2026, vs. $30.3M at December 31, 2025
- Cash runway into 2029 based on currently planned operations
- Q2 2026 R&D expenses $2.8M, down from $4.1M in Q2 2025
- Q2 2026 net loss $4.7M vs. $5.7M in Q2 2025
- Total operating expenses for first half 2026 $10.8M, down from $15.1M in first half 2025
- Stockholders’ equity $56.0M at June 30, 2026, vs. $28.6M at December 31, 2025
Negative
- Q2 2026 net loss $4.7M, continuing operating losses
- Q2 2026 G&A expenses $2.4M, up from $2.1M in Q2 2025
- Six‑month 2026 net loss $10.0M vs. $14.4M in six months 2025, still materially negative
- Weighted‑average shares 111.8M in Q2 2026 vs. 35.7M in Q2 2025, indicating significant dilution
News Explained
The second-quarter report shows weighted-average common shares of
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | 1Q26 earnings report | Positive | +12.1% | Cash runway and EQ504 development update accompanied reduced expenses and net loss. |
| Mar 25 | FY25 earnings report | Neutral | +0.0% | Results included no 2025 revenue, financing activity, and projected cash runway into 2029. |
| Nov 13 | 3Q25 earnings report | Negative | +23.8% | Revenue fell to zero while financing and clinical plans supported operations through 2027. |
| Mar 27 | FY24 earnings report | Negative | -35.6% | Phase 3 study missed its primary endpoint despite longer-term efficacy signals. |
| Nov 13 | 3Q24 earnings report | Positive | -12.3% | Revenue increased and net loss improved alongside continued clinical development plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-specific reactions were mixed, including +12.12%, 0%, +23.81%, -35.62%, and -12.33%, with both aligned and divergent outcomes.
Key Terms
aryl hydrocarbon receptor medical
pharmacokinetics medical
pharmacodynamics medical
ind-enabling regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter
Cash and cash equivalents of
LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and selective aryl hydrocarbon receptor (AhR) modulator.
“We continue to make meaningful progress advancing EQ504 toward the clinic," said Bruce Steel, Chief Executive Officer of Equillium. "Our colon-targeted formulated product has been manufactured, and we plan to submit the dossier for our Phase 1 study in Australia imminently. We expect to initiate this study in the fourth quarter of 2026 and report topline data approximately six months thereafter. The study is designed as a conventional randomized, double-blind, placebo-controlled single and multiple ascending dose study (SAD/MAD) in healthy volunteers, focused on safety, tolerability, pharmacokinetics and pharmacodynamics to assess proof of mechanism. Subject to supportive Phase 1 data, we anticipate expeditiously initiating a placebo-controlled study to assess the safety, tolerability, and efficacy of EQ504 in patients with moderately to severely active ulcerative colitis. Key study parameters are intended to leverage other AhR modulator clinical datasets in ulcerative colitis to facilitate an efficient patient proof-of-concept study.”
Recent Corporate & Clinical Highlights:
- Advancing EQ504 toward the clinic, with the Phase 1 proof-of-mechanism study expected to initiate in the fourth quarter of 2026, and topline data anticipated approximately six months thereafter.
- Initiated IND-enabling development activities for EQ504 as a potential inhaled therapy to treat inflammatory lung diseases.
- Initiated IND-enabling development activities for EQ302, an oral, bi-specific inhibitor of IL-15 and IL-21, intended to be developed for celiac disease.
- Established a Clinical Advisory Board chaired by Professor Bruce Sands, M.D. (Chair, Feinstein IBD Clinical Center, Mount Sinai) to guide the design and execution of the EQ504 clinical program in ulcerative colitis.
Second Quarter 2026 Financial Results
Cash and cash equivalents totaled
Research and development (R&D) expenses for the second quarter of 2026 were
General and administrative (G&A) expenses for the second quarter of 2026 were
Net loss for the second quarter of 2026 was
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to the advancement of EQ504 toward the clinic; the timing for the submission of Equillium’s dossier for its Phase 1 study in Australia, the timing of the initiation of the study, and the timing for the reporting of topline data from the study, if initiated; Equillium’s initiation of a placebo-controlled study to assess the safety, tolerability, and efficacy of EQ504 in patients, and the timing of the study if initiated; Equillium’s ability to leverage other AhR modulator clinical datasets in ulcerative colitis to facilitate an efficient proof-of-concept study; Equillium’s development of EQ504 as a potential inhaled therapy to treat inflammatory lung diseases; Equillium’s development of EQ302 for celiac disease; and the ability of Equillium’s cash runway to fund its currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to raise additional capital on terms acceptable to Equillium, or at all; Equillium’s ability to continue as a going concern; Equillium’s ability to execute its plans and strategies, and to execute its plans and strategies within its budgets; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and changes in Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
| Equillium, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands) | ||||||||
| (unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 57,164 | $ | 30,277 | ||||
| Prepaid expenses and other assets | 1,027 | 952 | ||||||
| Operating lease right-of-use assets | 475 | 658 | ||||||
| Total assets | $ | 58,666 | $ | 31,887 | ||||
| Current liabilities | ||||||||
| Accounts payable and other current liabilities | $ | 2,478 | $ | 2,934 | ||||
| Total current liabilities | 2,478 | 2,934 | ||||||
| Long-term operating lease liabilities | 172 | 356 | ||||||
| Total liabilities | 2,650 | 3,290 | ||||||
| Total stockholders' equity | 56,016 | 28,597 | ||||||
| Total liabilities and stockholders' equity | $ | 58,666 | $ | 31,887 | ||||
| Equillium, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 2,749 | $ | 4,083 | $ | 5,740 | $ | 10,007 | |||||||
| General and administrative | 2,406 | 2,145 | 5,025 | 5,091 | |||||||||||
| Total operating expenses | 5,155 | 6,228 | 10,765 | 15,098 | |||||||||||
| Loss from operations | (5,155 | ) | (6,228 | ) | (10,765 | ) | (15,098 | ) | |||||||
| Total other income, net | 462 | 489 | 761 | 705 | |||||||||||
| Net loss | $ | (4,693 | ) | $ | (5,739 | ) | $ | (10,004 | ) | $ | (14,393 | ) | |||
| Net loss per share, basic and diluted | $ | (0.04 | ) | $ | (0.16 | ) | $ | (0.10 | ) | $ | (0.40 | ) | |||
| Weighted-average number of common shares outstanding, basic and diluted | 111,805,635 | 35,719,317 | 104,085,316 | 35,653,455 | |||||||||||
